TargetBeta
LPA
lipoprotein(a) · also Lp(a), LP · Serine proteases
5 programs in company-led studies act on LPA, from 4 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| lepodisiran | Eli Lilly | lowers it | phase 3 | 83 running | – | a judged reading |
| muvalaplin | Eli Lilly | – | phase 3 | 61 running | – | a judged reading |
| HRS-5346 | Jiangsu HengRui Medicine | – | phase 2 | 63 running | – | the company's pipeline |
| DII235 | Novartis | lowers it | phase 2 | 11 running | – | the company's pipeline |
| JAR-2203rule | Beijing Jiake Ruikang Pharmaceutical Technology | lowers it | phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Atherosclerosis, 2 programs
- Renal Insufficiency, 2 programs
- Cardiovascular Diseases, 1 program
- Hyperlipoproteinemias, 1 program
- Liver Diseases, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 2027HRS-5346 · Jiangsu HengRui Medicine · phase 2 · NCT07767513
- Mar 2027lepodisiran · Eli Lilly · phase 3 · NCT07914738
- Apr 26, 2027DII235 · Novartis · phase 2 · NCT07235046
- Jul 30, 2027JAR-2203 · Beijing Jiake Ruikang Pharmaceutical Technology · phase 1 · NCT07937254
- Mar 2031muvalaplin · Eli Lilly · phase 3 · NCT07157774
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.